Formulation and Evaluation of Modified Release Matrix Tablets of Trimetazidine Dihydrochloride

The purpose of the present study was to formulate the oral modified release tablets of Trimetazidine dihydrochloride by using Polyethylene oxide (Polyox WSR 303 LEO) (35-55%) as a rate controlling polymer. The tablets were prepared by direct compression method and coated by using film coating polymers. The powder mixtures were evaluated for angle of repose, loose bulk density, tapped bulk density and compressibility index and showed satisfactory results. All the ingredients were lubricated and compressed using 8.5mm circular shaped standard concave plain punches. The tablets were evaluated for uniformity of weight, content of active ingredient, thickness, friability, hardness and In-vitro dissolution studies. Drug content in the formulation was determined by UV- Visible Spectrophotometric method. All the formulations showed compliance with Pharmacopoeial standards. The in vitro release study of matrix tablets were carried out in pH 6.8 phosphate buffer for 12 hours. The prepared matrix tablets showed 100.00% release over a period of 12 hours. The dissolution profile of Formulation, F5 was similar to Innovator product in three different media such as pH 1.2, pH 4.5 acetate buffer and pH 6.8 phosphate buffer. It was observed that the amount of polymer in the tablets influences the drug release. In vitro release study results revealed that the release of the drug was retarded with the proportional increase in polymer concentration. It was indicated that the using a hydrophilic non-cellulose polymer in an appropriate concentration in tablet could control the rate of drug release.